JPRN-UMIN000035110
Completed
未知
An exploratory study to evaluate the efficacy of enteral nutrition using thickening agents on physical properties in stomach and blood glucose fluctuation - The effect of enteral nutrition using thickening agents on physical properties in stomach and blood glucose fluctuation
Mejiro Second General Hospital0 sites6 target enrollmentDecember 3, 2018
ConditionsHealthy adult
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Healthy adult
- Sponsor
- Mejiro Second General Hospital
- Enrollment
- 6
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Subject who are pregnant or under lactation, or expected to be pregnant during the study 2\.Subjects who have serious history or receiving treatment of liver, kidney, heart, lung, digestive, hematological and metabolic disease 3\.Subjects who are chronic disease 4\.Subjects who have history of serious food or drug allergy 5\.Subjects who have fasting blood glucose 69\>\= or 100\<\= 6\.Subjects who have HbA1c 4\.5\>\= or 5\.6\<\= 7\.Subjects who are planning to participate in the other study during the study period 8\.Subjects judged inappropriate for the study by the principal investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
An exploratory study to evaluate the efficacy of novel enteral nutrition VVT-01 for nasal tube feeding patientsnasal tube feeding patientsJPRN-UMIN000036569Michinoo hospital20
Completed
Not Applicable
A exploratory study to evaluate the efficacy of the narrow band UVB therapy by Area selection type ultraviolet radiation treatment device in subjects with papuloerythroderma of Ofujipapuloerythroderma of OfujiJPRN-UMIN000031161Kobe University Graduate School of Medicine10
Completed
Not Applicable
An exploratory study to evaluate the efficacy of the single ingestion of milk protein hydrolysate on cerebral activity.JPRN-UMIN000025347Morinaga Milk Industry Co., LTD.36
Active, not recruiting
Phase 1
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.Chronic spontaneous urticaria and the following skin disorders:1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermatitis, dyshidrotic eczema, asteatotic eczema, lichen simplex chronicus).2 - Prurigo (acute prurigo, subacute prurigo, chronic prurigo).3 - Cutaneous pruritus (systemic cutaneous pruritus, local cutaneous pruritus).MedDRA version: 19.0Level: HLTClassification code 10012435Term: Dermatitis and eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10037083Term: PrurigoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10052568Term: Urticaria chronicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2016-001505-17-ESFAES FARMA, S.A.115
Active, not recruiting
Phase 1
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.EUCTR2016-001505-17-HUFAES FARMA, S.A.115